News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Santa Cruz discontinued a large number of its polyclonal products as a result of the USDA settlement that was made public May 19th 2016

Find CST Equivalent

To Purchase # 13621S

13621S 5 mg $99.00.0
$0.00

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

Western blot analysis of extracts from 293T cells, untreated (-) or treated with SB216763 (4 hr) at the indicated concentrations, using Non-phospho (Active) β-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb #8814 (upper), β-Catenin (D10A8) XP® Rabbit mAb #8480 (middle), or β-Actin (D6A8) Rabbit mAb #8457 (lower).

Learn more about how we get our images

Chemical structure of SB216763.

Learn more about how we get our images
Image

Product Usage Information

SB216763 is supplied as a lyophilized powder. For a 25 mM stock, reconstitute the 5 mg in 538.8 µl DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 5-25 µM for 3-24 hr.


Storage: Store lyophilized or in solution at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight:

371.20 g/mol


Purity:

>98%


Molecular Formula:

C19H12Cl2N2O2


The maleimide derivative SB216763 is a potent and selective cell permeable inhibitor of glycogen synthase kinase 3 (GSK-3). Research studies using peptide-based protein kinase assays show that SB216763 inhibits GSK-3α in an ATP competitive manner with an IC50 of 34 nM, and is an equally effective GSK3-β inhibitor. Similar assays demonstrate that SB216763 (at concentrations up to 10 µM) does not inhibit as many as 24 other serine/threonine and tyrosine protein kinases (1). As a consequence of inhibiting GSK-3, SB216763 stimulates glycogen synthesis in human liver cells (EC50 3.6 µM) via glycogen synthase activation and induces expression of a β-catenin regulated reporter gene in HEK293 cells (1). Furthermore, SB216763 induces accumulation of β-catenin, a key downstream effector in the Wnt signaling pathway, in many cell types (2-5). Additional research indicates that SB216763 can prevent neuronal cell death induced by PI3 kinase pathway inhibition (2). Glycogen synthase kinase 3 inhibitors such as SB216763 can be important research tools in studying the functional role of GSK-3 in cell signaling pathways.


1.  Coghlan, M.P. et al. (2000) Chem Biol 7, 793-803.

2.  Cross, D.A. et al. (2001) J Neurochem 77, 94-102.

3.  Piazza, F. et al. (2010) BMC Cancer 10, 526.

4.  Zhou, F. et al. (2011) Mol Biol Cell 22, 3533-40.

5.  Gebhardt, R. et al. (2010) J Cell Mol Med 14, 1276-93.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.

13621
SB216763